{"denomUnitsSelected":"Participants","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified by the protocol, the number of participants who experience an AE will be reported for the overall study according to treatment arm, defined as a treatment sequence arm in the protocol (i.e., \"Pembrolizumab Plus Berahyaluronidase alfa SC followed by Pembrolizumab IV\" and \"Pembrolizumab IV followed by Pembrolizumab plus Berahyaluronidase alfa SC\").","reportingStatus":"NOT_POSTED","timeFrame":"Up to ~27 months","title":"Number of Participants Who Experience an Adverse Event (AE)","type":"SECONDARY"}